Physician profile
Charles Lapp
NPI 1588778534
$2,957.97
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $374 · 2020: $352 · 2021: $836 · 2022: $648 · 2023: $674 · 2024: $74.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $748.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $415.89 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $374.34 | 2021 | |
| Pfizer INC. | $286.13 | 2019-2024 | |
| Bausch Health US, LLC | $253.61 | 2019-2023 | Aplenzin, Wellbutrin |
| Biohaven Pharmaceutical Holding Company Ltd. | $251.61 | 2022 | |
| Lilly USA, LLC | $188.17 | 2019-2021 | |
| Biodelivery Sciences International, INC. | $108.50 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.85 | 2019-2024 | Xifaxan, Trulance |
| Amgen INC. | $93.58 | 2020-2022 | |
| Collegium Pharmaceutical, INC. | $91.08 | 2023 | Belbuca, Xtampza |
| Eisai INC. | $78.14 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $75.37 | 2019 | |
| Forte Bio-Pharma LLC | $70.52 | 2022 | |
| Idorsia Pharmaceuticals US INC | $61.38 | 2022-2024 | Quviviq |
| Almatica Pharma LLC | $58.46 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $57.28 | 2019-2022 | |
| Harmony Biosciences LLC | $56.05 | 2023 | Wakix |
| Jazz Pharmaceuticals INC. | $52.04 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.45 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $40.60 | 2023 | Verquvo, Belsomra, Steglatro |
| Teva Pharmaceuticals USA, INC. | $37.70 | 2021 | |
| Astellas Pharma US INC | $29.97 | 2023 | Veozah |
| Novartis Pharmaceuticals Corporation | $20.16 | 2019 | |
| Daiichi Sankyo INC. | $19.40 | 2019 | |
| Grifols USA, LLC | $17.88 | 2020 | |
| Hikma Pharmaceuticals USA | $17.60 | 2021 | |
| Optinose US, INC. | $16.59 | 2021 | |
| Avadel Cns Pharmaceuticals, LLC | $16.32 | 2023 | Lumryz |
| Acella Pharmaceuticals, LLC | $11.66 | 2021 | |
| Shire North American Group INC | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Lapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.